by Instem Team | Aug 12, 2026 | Clinical
In clinical trial transparency, the terminology used in processes and reports is critical and can have significant downstream regulatory effects. The language used in an anonymization report influences how reviewers understand the strategy, how consistently teams...
by Instem Team | Aug 4, 2026 | Clinical
Life sciences organizations face a difficult balancing act: protecting patient privacy, meeting evolving global clinical trial transparency requirements, and maintaining sufficient data utility to support meaningful research. At the same time, clinical datasets and...
by Instem Team | Jul 2, 2026 | Clinical
Keeping up with regulatory compliance in clinical trials transparency (CTT) is demanding. Sponsors need to navigate overlapping, multi-jurisdictional obligations, each with distinct timelines, data formats, and requirements for confidential information1–3. This...
